Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

被引：0

作者：

Dimitrios Pectasides

Vasilios Karavasilis

George Papaxoinis

Georgia Gourgioti

Thomas Makatsoris

Georgia Raptou

Eleni Vrettou

Joseph Sgouros

Epaminontas Samantas

George Basdanis

Pavlos Papakostas

Dimitrios Bafaloukos

Vassiliki Kotoula

Haralambos P. Kalofonos

Chrisoula D. Scopa

George Pentheroudakis

George Fountzilas

机构：

[1] “Hippokration” Hospital,Oncology Section, Second Department of Internal Medicine

[2] Aristotle University of Thessaloniki School of Medicine,Department of Medical Oncology, “Papageorgiou” Hospital

[3] Section of Biostatistics,Division of Oncology, Department of Medicine

[4] Hellenic Cooperative Oncology Group,Department of Pathology

[5] Data Office,Third Department of Medical Oncology

[6] University Hospital,First Propaedeutic Department of Surgery, “AHEPA” Hospital

[7] University of Patras Medical School,Department of Medical Oncology

[8] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology

[9] “Agii Anargiri” Cancer Hospital,Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research

[10] Aristotle University of Thessaloniki School of Medicine,Department of Pathology

[11] “Hippokration” Hospital,Department of Medical Oncology

[12] “Metropolitan” Hospital,undefined

[13] Aristotle University of Thessaloniki School of Medicine,undefined

[14] University Hospital,undefined

[15] University of Patras Medical School,undefined

[16] Ioannina University Hospital,undefined

来源：

BMC Cancer | / 15卷

关键词：

Colorectal cancer; Adjuvant chemotherapy; Modified FOLFOX6; Capecitabine; Oxaliplatin; Prognosis; KRAS; Microsatellite instability;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
Pectasides, Dimitrios
Karavasilis, Vasilios
Papaxoinis, George
Gourgioti, Georgia
Makatsoris, Thomas
Raptou, Georgia
Vrettou, Eleni
Sgouros, Joseph
Samantas, Epaminontas
Basdanis, George
Papakostas, Pavlos
Bafaloukos, Dimitrios
Kotoula, Vassiliki
Kalofonos, Haralambos P.
Scopa, Chrisoula D.
Pentheroudakis, George
Fountzilas, George
BMC CANCER, 2015, 15
[2] Pilot study of the combination of capecitabine plus oxaliplatin as adjuvant therapy for patients with stage III and high risk stage II colon cancer
Olier, C.
Reyna, C.
Aramendia, J. M.
Rodriguez, J.
Viudez, A.
Chopitea, A.
Garcia-Foncillas, J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[3] Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66 years or older
Jones, Emily
Duan, Zhigang
Nguyen, Thinh T.
Giordano, Sharon H.
Zhao, Hui
CANCER MEDICINE, 2023, 12 (03): : 2389 - 2406
[4] Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
Tabernero, Josep
Garcia-Carbonero, Rocio
Cassidy, James
Sobrero, Alberto
Van Cutsem, Eric
Koehne, Claus-Henning
Tejpar, Sabine
Gladkov, Oleg
Davidenko, Irina
Salazar, Ramon
Vladimirova, Liubov
Cheporov, Sergey
Burdaeva, Olga
Rivera, Fernando
Samuel, Leslie
Bulavina, Irina
Potter, Vanessa
Chang, Yu-Lin
Lokker, Nathalie A.
O'Dwyer, Peter J.
CLINICAL CANCER RESEARCH, 2013, 19 (09) : 2541 - 2550
[5] A multicenter phase 2 clinical trial testing a combination of oxaliplatin, bolus 5-fluorouracil, leucovorin and capecitabine in patients with metastatic colorectal cancer (MCRC)
LoConte, N. K.
Holen, K. D.
Eickhoff, J.
Dzelak, T.
Richie, K.
Teeter, K.
Warren, D.
Jumonville, A. J.
Kwong, R. W.
Mulkerin, D. L.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[6] Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer
Said, Rabih
Ye, Yang
Hong, David S.
Naing, Aung
Falchook, Gerald
Fu, Siqing
Wheler, Jennifer J.
Piha-Paul, Sarina
Tsimberidou, Apostolia-Maria
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (03) : 575 - 581
[7] Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as adjuvant treatment for stage II and III rectal cancer
Jin, J.
Li, Y. X.
Wang, W. H.
Liu, Y. P.
Wang, K.
Fang, H.
Zhou, Z. X.
Zhou, A. P.
Wang, J. W.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S284 - S285
[8] Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer
Rabih Said
Yang Ye
David S. Hong
Aung Naing
Gerald Falchook
Siqing Fu
Jennifer J. Wheler
Sarina Piha-Paul
Apostolia-Maria Tsimberidou
Cancer Chemotherapy and Pharmacology, 2016, 77 : 575 - 581
[9] Phase III study of 5-fluorouracil/leucovorin plus oxaliplatin versus capecitabine plus oxaliplatin as first line therapy in patients with advanced colorectal cancer (ACRC)
Porschen, R
Arkenau, T
Kubicka, S
Schmoll, HJ
Seufferlein, T
Graeven, U
Grothey, A
GASTROENTEROLOGY, 2005, 128 (04) : A438 - A438
[10] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
Jeong Eun Kim
Yong Sang Hong
Hwa Jung Kim
Kyu-pyo Kim
Sun Young Kim
Seok-Byung Lim
In Ja Park
Chan Wook Kim
Yong Sik Yoon
Chang Sik Yu
Jin Cheon Kim
Ji Hun Kim
Tae Won Kim
Annals of Surgical Oncology, 2017, 24 : 1289 - 1294

← 1 2 3 4 5 →